CU20120042A7 - (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer - Google Patents

(heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer

Info

Publication number
CU20120042A7
CU20120042A7 CU20120042A CU20120042A CU20120042A7 CU 20120042 A7 CU20120042 A7 CU 20120042A7 CU 20120042 A CU20120042 A CU 20120042A CU 20120042 A CU20120042 A CU 20120042A CU 20120042 A7 CU20120042 A7 CU 20120042A7
Authority
CU
Cuba
Prior art keywords
heteroarilmetil
cancer drugs
thiohydantoins
substituted
substituted thiohydantoins
Prior art date
Application number
CU20120042A
Other languages
English (en)
Spanish (es)
Inventor
Horst Irlbacher
Gimenez Hortensia Faus
Bernard Haendler
Silke Koehr
Arwed Cleve
Ulrich Luecking
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20120042A7 publication Critical patent/CU20120042A7/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CU20120042A 2009-09-11 2012-03-09 (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer CU20120042A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17

Publications (1)

Publication Number Publication Date
CU20120042A7 true CU20120042A7 (es) 2012-06-21

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120042A CU20120042A7 (es) 2009-09-11 2012-03-09 (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer

Country Status (28)

Country Link
US (1) US20120251551A1 (enExample)
EP (1) EP2475653A1 (enExample)
JP (1) JP2013504523A (enExample)
KR (1) KR20120065396A (enExample)
CN (1) CN102639523A (enExample)
AR (1) AR078166A1 (enExample)
AU (1) AU2010294588A1 (enExample)
BR (1) BR112012005526A2 (enExample)
CA (1) CA2773591A1 (enExample)
CL (1) CL2012000623A1 (enExample)
CO (1) CO6511228A2 (enExample)
CR (1) CR20120113A (enExample)
CU (1) CU20120042A7 (enExample)
DO (1) DOP2012000063A (enExample)
EA (1) EA201200473A1 (enExample)
EC (1) ECSP12011716A (enExample)
IL (1) IL218390A0 (enExample)
IN (1) IN2012DN02081A (enExample)
MA (1) MA33566B1 (enExample)
MX (1) MX2012002977A (enExample)
NZ (1) NZ598643A (enExample)
PE (1) PE20121180A1 (enExample)
PH (1) PH12012500497A1 (enExample)
SG (1) SG178919A1 (enExample)
TN (1) TN2012000108A1 (enExample)
TW (1) TW201111378A (enExample)
UY (1) UY32882A (enExample)
WO (1) WO2011029537A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102399A1 (ja) 2010-02-17 2011-08-25 武田薬品工業株式会社 複素環化合物
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2013096679A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
KR102327888B1 (ko) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
CA3161836A1 (en) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP3083596A1 (en) 2013-12-18 2016-10-26 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
EP3140300B1 (en) 2014-05-07 2019-08-14 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
EP3359544B1 (en) 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
EP3625215B1 (en) 2017-05-18 2023-09-13 PI Industries Ltd Formimidamidine compounds useful against phytopathogenic microorganisms
IL276437B2 (en) 2018-02-13 2024-03-01 Bayer Ag Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
CA3132963A1 (en) 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
AU2021209875A1 (en) * 2020-01-21 2022-08-11 Georgia Tech Research Corporation Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
WO2005005399A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
EP1673348B1 (en) 2003-09-30 2009-04-01 Janssen Pharmaceutica N.V. Benzoimidazole compounds
BRPI0418078A8 (pt) 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
US7803826B2 (en) 2004-08-03 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivatives
EP1790640A4 (en) * 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
AU2005311534B2 (en) 2004-12-03 2011-02-17 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as H3 antagonists
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
AR069039A1 (es) 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
JP2013504523A (ja) 2013-02-07
CN102639523A (zh) 2012-08-15
MA33566B1 (fr) 2012-09-01
IL218390A0 (en) 2012-04-30
AU2010294588A1 (en) 2012-04-05
UY32882A (es) 2011-04-29
KR20120065396A (ko) 2012-06-20
US20120251551A1 (en) 2012-10-04
EP2475653A1 (en) 2012-07-18
BR112012005526A2 (pt) 2016-04-26
EA201200473A1 (ru) 2012-10-30
CL2012000623A1 (es) 2012-09-14
DOP2012000063A (es) 2012-05-15
TW201111378A (en) 2011-04-01
CO6511228A2 (es) 2012-08-31
CR20120113A (es) 2012-05-02
IN2012DN02081A (enExample) 2015-08-21
NZ598643A (en) 2013-10-25
ECSP12011716A (es) 2012-04-30
CA2773591A1 (en) 2011-03-17
TN2012000108A1 (en) 2013-09-19
PE20121180A1 (es) 2012-08-24
WO2011029537A1 (en) 2011-03-17
MX2012002977A (es) 2012-04-30
AR078166A1 (es) 2011-10-19
PH12012500497A1 (en) 2012-10-22
SG178919A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
SV2012004192A (es) Nuevo uso antitumoral de cabazitaxel
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CO6501171A2 (es) Derivados de quinoxalina y su uso para el tratamiento de tumores benignos y malignos
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
CL2010001424A1 (es) Compuestos derivados de azacarbolinas; compuestos intermediarios; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento del cancer.
CL2008001216A1 (es) Compuestos derivados de pirazol-3-il-amino-pirimidina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2010001615A1 (es) Uso de eufol en el tratamiento de la inflamacion y el dolor neuropatico.
CU20100004A7 (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k